Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17019782 | 1.00 | TSHR (0.58) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL6748142 | 0.92 | CTSL (0.51) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL4677170 | 0.92 | TSHR (0.54) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL6649338 | 0.92 | TSHR (0.54) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL23744979 | 0.91 | CTSL (0.50) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL17043033 | 0.91 | CTSL (0.50) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL17043034 | 0.91 | CTSL (0.50) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL5526823 | 0.91 | CTSL (0.50) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL2374859 | 0.91 | CTSL (0.50) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL5526821 | 0.91 | CTSL (0.50) | TSHRCTSLCTSBCTSKNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780026-A2 | HCV NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-09-24 | — | — | EP | claimed |
| WO-2013074386-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | claimed |
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244615-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230331712-A1 | SOLID FORMS OF (R)-1(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2022068929-A1 | PYRIMIDINEDIONE COMPOUND AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-04-07 | — | — | WO | disclosed |
| WO-2020002314-A1 | RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND | F. HOFFMANN-LA ROCHE AG (CH) | 2020-01-02 | — | — | WO | disclosed |
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| CN-108419435-A | Compound and epigenetics for treating cancer | 新加坡科技研究局 | 2018-08-17 | — | — | CN | disclosed |
| US-9328138-B2 | HCV NS3 protease inhibitors | MSD ITALIA S.R.L. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-20150320736-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-12 | — | — | US | disclosed |
| US-20100280068-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100113513-A1 | QUINOLINE DERIVATIVES AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010037836-A2 | CROSS-SPECIES-SPECIFIC PSMAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY | MICROMET AG (DE) | 2010-04-08 | — | — | WO | disclosed |
| US-20100056570-A1 | FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2008106225-A1 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080171767-A1 | N-substituted-2-alkylthio-2-(substituted aryloxy and heteroaryloxy)alkylamides and their sulphinyl and sulphonyl derivatives such as 2-(3,5-dichlorophenoxy)-2-methylthio-N-2-methylprop-2-yl acetamide; fungal infections of plants | SYNGENTA CROP PROTECTION, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| EP-0250360-A3 | SUBSTITUTED BENZYL-CYCLOPROPYL-METHYL-ETHERS | CIBA-GEIGY AG (CH) | 1988-11-30 | — | — | EP | disclosed |
| EP-0268560-A2 | Substituted phenoxybenzyl-(dihalogen-dimethyl-cyclopropyl-methyl) ether | CIBA-GEIGY AG (CH) | 1988-05-25 | — | — | EP | disclosed |
| EP-0250360-A2 | Substituted benzyl-cyclopropyl-methyl-ethers | CIBA-GEIGY AG (CH) | 1987-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171767-A1 | N-substituted-2-alkylthio-2-(substituted aryloxy and heteroaryloxy)alkylamides and their sulphinyl and sulphonyl derivatives such as 2-(3,5-dichlorophenoxy)-2-methylthio-N-2-methylprop-2-yl acetamide; fungal infections of plants | NAT1, DPM1, AADAC | TSHR 3776/4885CTSL 4311/4885CTSB 4256/4885 |
| US-20150320736-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | CFTR, SLC26A4, PKD1 | TSHR 1730/4885CTSL 1943/4885CTSB 2363/4885 |
| US-20230331712-A1 | SOLID FORMS OF (R)-1(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR1A, HTR1D | TSHR 2791/4885CTSL 1364/4885CTSB 2101/4885 |
| US-20100056570-A1 | FUNGICIDES | CYP21A2, CYP51A1, CYP4X1 | TSHR 1125/4885CTSL 2259/4885CTSB 2948/4885 |
| US-20100113513-A1 | QUINOLINE DERIVATIVES AS FUNGICIDES | CYP1A1, CYP4X1, CYP3A7 | TSHR 2730/4885CTSL 2493/4885CTSB 2699/4885 |
| US-20100280068-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES | CYP1A1, CYP3A7, CYP1A2 | TSHR 2697/4885CTSL 2222/4885CTSB 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.